The 31 references in paper O. Lebedinskaya V., I. Kabanovskaja N., N. Akhmatova K., E. Lebedinskaya A., A. Lazareva V., M. Kiselevsky V., О. Лебединская В., И. Кабановская Н., Н. Ахматова К., Е. Лебединская А., А. Лазарева В., М. Киселевский В. (2014) “НАТУРАЛЬНЫЕ КИЛЛЕРЫ Т-КЛЕТКИ ЛЕЙКОЦИТАРНЫХ ИНФИЛЬТРАТОВ ПЕЧЕНИ БОЛЬНЫХ С ОПУХОЛЕВЫМ ПРОЦЕССОМ И ВИРУСНЫМ ГЕПАТИТОМ // NATURAL KILLER T CELLS IN HEPATIC LEUCOCYTE INFILTRATES IN PATIENTS WITH MALIGNANT PROCESS AND VIRAL HEPATITIS” / spz:neicon:mimmun:y:2010:i:2:p:20-40

1
Chang Y.J., Huang J.R., Tsai Y.C., Hung J.T., Wu D., Fujio M., Wong C.H., Yu A.L. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids // Proc. Natl. Acad. Sci. USA. – 2007. – Vol. 104, N 25. – P. 10299-10304.
(check this in PDF content)
2
Crowe N.Y., Uldrich A.P., Kyparissoudis K., Hammond K.J., Hayakawa Y., Sidobre S., Keating R., Kronenberg M., Smyth M.J., Godfrey D.I. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells // J. Immunol. – 2003. – Vol. 171. – P. 4020-4027.
(check this in PDF content)
3
Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., Krasovsky J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma // J. Exp. Med. – 2003. – Vol. 197. – P.1667-1676.
(check this in PDF content)
4
Exley M.A., Koziel M.J. To Be or Not to Be NKT: Natural Killer T Cells in the Liver // Hepatology. – 2004. – Vol. 40, N 5. – P. 1033-1040.
(check this in PDF content)
5
Exley M.A., He Q., Cheng O., Wang R.J., Cheney C.P., Balk S.P., Koziel M.J. Cutting edge: compartmentalization of Th1-like noninvariant CD1dreactive T cells in hepatitis C virus-infected liver // J. Immunol. – 2002. – Vol. 168. – P. 1519-1523.
(check this in PDF content)
6
Fuji N., Ueda Y., Fujiwara H., Toh T., Yoshimura T., Yamagishi H. Antitumor effect of a-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver // Clinical Cancer Research. – 2000. – Vol. 6, N 8. – P. 3380-3387.
(check this in PDF content)
7
Fuji S., Shimizu K., Smith C. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein // J. Exp. Med. – 2003. – Vol. 198. – P. 267-279.
(check this in PDF content)
8
Godfrey D.I., MacDonald H.R., Kronenberg M.M., Smyth M.J., Van Kaer L. NKT cells: what’s in a name? // Nat. Rev. Immunol. – 2004. – Vol. 4. – P. 231-237.
(check this in PDF content)
9
Hammond K.J.L., Pelikan S.B., Crowe N.Y., Randle-Barrett E., Nakayama T., Taniguchi M., Smyth M.J., van Driel I.R., Scollay R., Baxter A.G., Godfrey D.I. NKT cells are phenotypically and functionally diverse // Eur. J. Immunol. – 1999. – Vol. 29. – P. 3768-3781.
(check this in PDF content)
10
Kakimi K., Guidotti L.G., Koezuka Y., Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo // J. Exp. Med. – 2000. – Vol. 192, N 7. – P. 921-930. Таблица 5. NK-акТивносТь и циТоТоксичносТь мононуклеаРных лейкоциТов (мл), выделенных из печени и селезенки мышей, поРаженных опухолевым пРоцессом, по оТношению к опухоли Yас -1 и ау Тологичным опухолевым клеТкам Клетки-эффекторы Цитотоксический индекс, % клетки-мишени YАС-1аутологичные опухолевые клетки МЛ печени61±14*43±11* МЛ селезенки37±1018±8 примечание. * – достоверные различия по сравнению с МЛ селезенки при p < 0,05.
(check this in PDF content)
11
Kenna T., Mason L.G., Porcelli S.A., Koezuka Y., Hegarty J.E., O’Farrelly C., Doherty D.G. NKT cells from normal and tumor-bearing human liver are phenotypically and functionally distinct from murine NKT cells // J. Immunol. – 2003. – Vol. 166, N 11. – P. 6578-6584.
(check this in PDF content)
12
Kenna T., Mason L.G., Porcelli S.A., Koezuka Y., Hegarty J.E., O’Farrelly C., Doherty D.G. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells // J. Immunol. – 2003. – Vol. 171. – P. 1775-1779.
(check this in PDF content)
13
Kenna T., Golden-Mason L., Porcelli S.A., Koezuka Y., Hegarty J.E., O’Farrelly C., Doherty D.G. CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver // Cancer Immunol Immunother. – 2007. – Vol. 56, N 4. – P. 563-72.
(check this in PDF content)
14
Kikuchi A., Nieda M., Koezuka Y., Ishihara S., IshikawaY., Tadokoro K., Durrant S., Boyd S., Juji T., Nicol A. In vitro anti-tumour activity of alphagalactosylceramide-stimulated human invariant Valpha24 + NKT cells against melanoma // Br. J. Cancer. – 2001. – Vol. 85. – P. 741-746.
(check this in PDF content)
15
Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., Sato M., Takeda K., Okumura K., Van Kaer L., Kawano T., Taniguchi M., Nishimura T. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells // J. Exp. Med. – 1999. – Vol. 189. – P. 1121-1127.
(check this in PDF content)
16
Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes // Annual review of immunology. – 2005. – Vol. 23. – P. 877-900.
(check this in PDF content)
17
Levy O., Orange J.S., Hibberd P., Steinberg S., LaRussa P., Weinberg A., Wilson S.B., Shaulov A., Fleisher G., Geha R.S., Bonilla F.A., Exley M. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a ovel deficiency in natural killer T cells // J. Infect. Dis. – 2003. – Vol. 188. – P. 948-953.
(check this in PDF content)
18
Matsuda J.L., Gapin L., Baron J.L., Sidobre S., Stetson D.B., Mohrs M., Locksley R.M., Kronenberg M. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo // Proc. Natl. Acad. Sci. U. S. A. – 2003. – Vol. 100. – P. 8395-8400.
(check this in PDF content)
19
Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., Kronenberg M., Seeger R.C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells // J. Immunol. – 2001. – Vol. 167. – P. 3114-3122.
(check this in PDF content)
20
Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., Kamada N., Iizasa T., Nakayama T., Fujisawa T., Taniguchi M. Preserved IFN-alpha production of circulating V alpha 24 NKT cells in primary lung cancer patients // Int. J. Cancer. – 2002. – Vol. 102. – P. 159-165.
(check this in PDF content)
21
Pillai A.B., George T.I., Dutt S., Teo P., Strober S. NKT cells can prevent graft-versushost disease and permit graft antitumor activity after bone marrow transplantation. // J. Immunol. – 2007. – Vol. 178, N 10. – P. 6242-51.
(check this in PDF content)
22
Poulton L.D., Smyth M.J., Hawke C.G., Silveira P., Shepherd D., Naidenko O.V., Godfrey D.I., Baxter A.G. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice // Int. Immunol. – 2001. – Vol. 13. – P. 887-896.
(check this in PDF content)
23
Seino K., Motohashi S., Fujisawa T., Nakayama T., Taniguchi M. Natural killer T cellmediated antitumor i mmune responses and their clinical applications // Cancer Sci. – 2006. – Vol. 97, N 9. – P. 807-812.
(check this in PDF content)
24
Smyth M.J., Godfrey D.I. NKT cells and tumor immunity-a double-edged sword // Nat. Immunol. – 2000. – Vol. 1. – P. 459-460.
(check this in PDF content)
25
Smyth M.J., Crowe N.Y., Takeda K. NKT cells – conductors of tumor immunity? // Curr. Opin. Immunol. – 2002. – Vol. 14. – P. 165-171.
(check this in PDF content)
26
Sonoda K.H., Taniguchi M., Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells // J. Immunol. – 2002. – Vol. 168. – P. 2028-2034.
(check this in PDF content)
27
Spadaro M., Curcio C., Varadhachary A., Cavallo F., Engelmayer J., Blezinger P., Pericle F., Forni G. Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrininduced inhibition of neu + tumors // Cancer Res. – 2007. – Vol. 67, N 13. – P. 6425-32.
(check this in PDF content)
28
Swann J.B., Coquet J.M., Smyth M.J., Godfrey D.I. CD1-restricted T cells and tumor immunity // Curr. Top. Microbiol. Immunol. – 2007. – Vol. 314. – P. 293-323.
(check this in PDF content)
29
Trobonjaca Z., Leithuser F., Mller P., Schirmbeck R., Reimann J. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFNγ release by liver NKT cells // J. Immunol. – 2001. – Vol. 167, N 3. – P. 1413-1422.
(check this in PDF content)
30
Trobonjaca Z., Kroger A., Stober D., Leithuser F., Mller P., Hauser H., Schirmbeck R., Reimann J. Activating immunity in the liver. II. IFNb attenuates NK cell-dependent liver injury triggered by liver NKT cell activation // J. Immunol. – 2002. – Vol. 168, N 8. – P. 3763-3770.
(check this in PDF content)
31
Wilson S.B., Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity // Nat. Rev. Immunol. – 2003. – Vol. 3. – P. 211-222. поступила в редакцию 01.07.2008
(check this in PDF content)